DABIGATRAN ETEXILATE MESYLATE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, preventing fibrinogen cleavage and clot formation.
| Metabolism | Hydrolyzed by esterases to active metabolite dabigatran; minimal CYP450 metabolism; substrate of P-glycoprotein (P-gp). |
| Excretion | Renal: 80% unchanged drug via glomerular filtration and tubular secretion; Fecal: ~6% via biliary secretion; Hepatic metabolism (minor) via esterase-mediated hydrolysis to glucuronide conjugates (less than 5% of dose). |
| Half-life | Terminal elimination half-life: 12–17 hours (mean ~14 hours) in healthy adults; prolonged to 15–34 hours in moderate renal impairment (CrCl 30–50 mL/min); no significant change in mild hepatic impairment. Clinical context: Supports twice-daily dosing; accumulation risk in renal impairment. |
| Protein binding | 35% bound to plasma proteins (primarily albumin); not displaced by highly protein-bound drugs (e.g., warfarin, NSAIDs) due to low binding affinity. |
| Volume of Distribution | Volume of distribution: 0.6–0.7 L/kg (mean 0.65 L/kg) indicating moderate tissue distribution; higher in elderly (up to 0.8 L/kg due to reduced lean body mass). Clinical meaning: Not extensively distributed, consistent with low lipophilicity; Vd increases with age and renal impairment. |
| Bioavailability | Oral bioavailability: 6.5% (range 5–11%) after prodrug conversion; absorption is pH-dependent via P-glycoprotein transport; food delays absorption but does not reduce total exposure; co-administration with P-glycoprotein inducers/inhibitors alters bioavailability. |
| Onset of Action | Oral: Peak anticoagulant effect (measured by dilute thrombin time, ecarin clotting time) achieved 2 hours after administration; measurable effect within 30 minutes; onset of therapeutic anticoagulation occurs within 1–2 hours. |
| Duration of Action | Duration of anticoagulant effect: ~24 hours after single dose; steady-state achieved within 2–3 days with twice-daily dosing; effective antithrombotic action persists for 12 hours after last dose; elevated risk of bleeding up to 24 hours post-dose in renal impairment. |
150 mg orally twice daily
| Dosage form | CAPSULE |
| Renal impairment | CrCl >30 mL/min: 150 mg twice daily; CrCl 15-30 mL/min: 75 mg twice daily; CrCl <15 mL/min or dialysis: contraindicated |
| Liver impairment | Child-Pugh class A or B: no adjustment; Child-Pugh class C: not recommended |
| Pediatric use | Weight-based: <11 kg: no data; 11-21 kg: 75 mg twice daily; 22-40 kg: 110 mg twice daily; >40 kg: 150 mg twice daily (for venous thromboembolism treatment) |
| Geriatric use | Age ≥80 years: consider 75 mg twice daily due to increased bleeding risk; monitor renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
P-gp inducers (eg rifampin) decrease levels and P-gp inhibitors (eg dronedarone) increase levels Risk of serious and sometimes fatal bleeding.
| Breastfeeding | Excreted in human milk at low levels; M/P ratio unknown. Insufficient data to assess risk; avoid breastfeeding or use with caution due to potential bleeding risk in the infant. |
| Teratogenic Risk | First trimester: Limited data; animal studies show no major malformations but increased risk of hemorrhage. Second/third trimester: Risk of fetal hemorrhage, placental abruption, and preterm labor; contraindicated due to bleeding risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Premature discontinuation of dabigatran increases the risk of thrombotic events. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture, resulting in long-term or permanent paralysis.
| Common Effects | Nausea Anemia low number of red blood cells Gastrointestinal bleeding Dyspepsia Diarrhea Abdominal pain Nosebleeds Skin bleeding |
| Serious Effects |
Active pathological bleeding; history of serious hypersensitivity reaction to dabigatran; mechanical prosthetic heart valve; significant hepatic impairment or coagulopathy; epidural or spinal puncture without adequate anticoagulation management.
| Precautions | Risk of bleeding including intracranial and gastrointestinal hemorrhage; discontinue before surgery; avoid concomitant use with P-gp inducers; caution in renal impairment (dose adjustment required); increased risk of gastrointestinal bleeding in elderly; risk of thrombotic events if discontinued prematurely. |
Loading safety data…
| Monitor maternal INR, aPTT, and bleeding signs. Fetal ultrasound for growth and amniotic fluid volume; assess for signs of hemorrhage. |
| Fertility Effects | No adverse effects on fertility observed in animal studies; human data lacking. |
| Food/Dietary | No significant food interactions. Dabigatran etexilate mesylate can be taken with or without food. A high-fat meal delays absorption but does not affect total exposure. Grapefruit juice and other foods that affect CYP enzymes or P-glycoprotein (P-gp) are not expected to interact significantly, but caution with P-gp inhibitors (e.g., verapamil, amiodarone, clarithromycin, ketoconazole) which may increase dabigatran levels. Avoid St. John’s wort and rifampin as they induce P-gp and reduce dabigatran effectiveness. |
| Clinical Pearls | Dabigatran etexilate mesylate is a prodrug of dabigatran, a direct thrombin inhibitor. It is renally eliminated; dose adjustments required for CrCl 15-50 mL/min. Contraindicated in CrCl < 15 mL/min or on dialysis. Avoid in patients with mechanical prosthetic heart valves due to increased thromboembolic risk. Idarucizumab is the specific reversal agent. No routine coagulation monitoring is required, but activated partial thromboplastin time (aPTT) can assess anticoagulant effect. Twice-daily dosing is necessary due to short half-life. Risk of dyspepsia and GI bleeding is higher than with warfarin. Do not open capsules; can increase oral bioavailability by 75%. Convert from warfarin: start when INR < 2.0. Convert to warfarin: start warfarin 3 days before discontinuing dabigatran if CrCl > 50 mL/min; earlier if CrCl lower. |
| Patient Advice | Take exactly as prescribed; do not skip doses or take double doses. · Swallow capsules whole; do not crush, chew, or open them. · You can take with or without food, but consistency matters—take at same times each day. · Contact your doctor or seek emergency care if you have signs of bleeding: unusual bruising, nosebleeds, blood in urine/stool, coughing/vomiting blood, or heavy menstrual bleeding. · Do not stop taking this medication without consulting your doctor; stopping increases clot risk. · Tell all healthcare providers you are taking dabigatran before any surgery or dental procedures. · Store in original bottle, tightly closed; remove capsules only when ready to use. Do not put in pill organizers; moisture reduces effectiveness. Use within 4 months of opening. · Avoid aspirin, ibuprofen, naproxen, or other NSAIDs unless prescribed; they increase bleeding risk. · If you miss a dose and it is less than 6 hours until next dose, skip missed dose; otherwise take it as soon as remembered. Do not double up. · Wear a medical alert bracelet or carry a card stating you are on dabigatran. |